| Literature DB >> 35984607 |
Susan P Buchbinder1,2,3,4, Aaron J Siegler5, Kenneth Coleman6, Eric Vittinghoff7, Gretchen Wilde5, Annie Lockard5, Hyman Scott6,8, Peter L Anderson9, Nicole Laborde10, Ariane van der Straten8,11, Richard H Christie12, Michelle Marlborough12, Albert Y Liu6,8.
Abstract
Measurement of adherence to oral pre-exposure prophylaxis (PrEP) in real-time has been challenging. We developed DOT Diary, a smartphone application that combines automated directly observed therapy with a PrEP adherence visualization toolkit, and tested its ability to measure PrEP adherence and to increase adherence among a diverse cohort of young men who have sex with men (MSM). We enrolled 100 MSM in San Francisco and Atlanta and randomly assigned them 2:1 to DOT Diary versus standard of care. Concordance between DOT Diary measurement and drug levels in dried blood spots was substantial, with 91.0% and 85.3% concordance between DOT Diary and emtricitabine-triphosphate and tenofovir-diphosphate, respectively. There was no significant difference in the proportion of participants with detectable PrEP drug levels at 24 weeks between study arms. These results suggest DOT Diary is substantially better than self-reported measures of adherence, but additional interventions are needed to improve PrEP adherence over time.Entities:
Keywords: Adherence; Artificial intelligence (AI); Directly observed therapy (DOT); Men who have sex with men (MSM); Pre-exposure prophylaxis (PrEP)
Year: 2022 PMID: 35984607 DOI: 10.1007/s10461-022-03805-3
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165